Search

Search Constraints

You searched for: Author/Creator Graham, Daniela

Search Results

2. AB0440 CHANGES IN KEY LABORATORY VALUES WITH TOFACITINIB 5 MG BID TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS. (June 2019)

3. Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers. Issue 3 (9th May 2022)

4. FRI0452 TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DERMATOLOGIC ENDPOINTS FROM 2 PHASE 3 STUDIES. (June 2019)

5. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. Issue 1 (15th January 2021)

6. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. Issue 1 (15th January 2021)

7. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. Issue 1 (15th January 2021)

8. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. Issue 1 (15th January 2021)

9. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Issue 11 (5th August 2020)

10. Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis. Issue 12 (29th November 2018)